OncoSil Medical Limited (ASX:OSL) Completes PANCOSIL Study Recruitment
Study Completion
OncoSil Medical Limited (ASX: OSL) has successfully completed patient recruitment for the PANCOSIL trial, marking a significant milestone in its clinical development strategy. The open-label, single-arm Phase 1–2 feasibility study, conducted by Amsterdam University Medical Center, evaluated the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil™ device in 20 patients with non-progressive locally advanced pancreatic cancer.
Future Outlook
The company anticipates preliminary data from the PANCOSIL study to be available in late 2025, which will support the wider adoption and market penetration of the OncoSil™ device.
Executive Comments
CEO Nigel Lange stated, “The completion of recruitment in the PANCOSIL study represents a critical milestone in the clinical development of the OncoSil™ device. On behalf of OncoSil Medical, I want to thank Professor Besselink and the entire Amsterdam UMC team for their leadership and vision over the design and implementation stages of the PANCOSIL study. The study’s importance to our device’s development process cannot be over-estimated, with it representing a major opportunity to unlock new pathways for delivering our therapy and accelerating its adoption in clinical practice. We now look forward to the results from the PANCOSIL study and expect that they will make an invaluable contribution to our efforts to make the OncoSil™ device a go-to treatment for patients with unresectable locally advanced pancreatic cancer – one that has acknowledged flexibility and is widely accessible.”
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
